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Abstract
Objective: To determine pregnancy outcome in patients
with short cervix on transvaginal ultrasound between 16
and 24 weeks’ gestation treated with McDonald cerclage
compared to weekly intramuscular injections of 17 a-
hydroxyprogesterone caproate (17OHP-C).
Methods: From November 2003 through December
2006, asymptomatic, singleton pregnancies were scre-
ened with transvaginal ultrasound between 16–24
weeks’ gestation. Patients with a cervical length (CL)
F25 mm were offered enrollment. Patients were random-
ly assigned to treatment with McDonald cerclage or
weekly intramuscular injections of 17OHP-C. The primary
outcome was spontaneous preterm birth (PTB) prior to
35 weeks’ gestation.
Results: Seventy-nine patients met inclusion criteria; 42
were randomly assigned to the cerclage and 37 to
17OHP-C. Spontaneous PTB prior to 35 weeks’ gesta-
tion occurred in 16/42 (38.1%) of the cerclage group and
in 16/37 (43.2%) of the 17OHP-C group (relative risk,
1.14 95% CI, 0.67, 1.93). A post hoc analysis of patients
with a prior PTB showed no difference in spontaneous
PTB -35 weeks between groups. A similar analysis of
patients with a CLF15 mm showed a reduction in spon-
taneous PTB -35 weeks in the cerclage group (relative
risk 0.48, 0.24–0.97).
*Presented at the 27th Annual Meeting of the Society for Mater-
nal-Fetal Medicine, February 5–10, 2007, San Francisco, CA.
**No financial support was used to perform this study. It was
funded under the administrative budget of the Department of
Obstetrics and Gynecology, Lehigh Valley Hospital.
***Corresponding author:
Sean M. Keeler, MD
Lehigh Valley Health Network
1200 S. Cedar Crest Blvd.
Allentown
PA 18103
USA
Tel.: q1-610-402-1221
Fax: q1-610-402-1328
E-mail: sean.keeler@gmail.com
Conclusion: Women with CL F25 mm in the second-
trimester appear to have similar risks of delivering prior
to 35 weeks’ gestation when treated with 17OHP-C or
McDonald cerclage. However, cerclage may be more
effective in preventing spontaneous PTB in women with
CLF15 mm.
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Introduction
The pathophysiology of spontaneous preterm birth (PTB)
continues to elude investigators as the rate of premature
birth continues to rise in the US w10x. Measurement of
cervical length (CL) by transvaginal ultrasound is a pow-
erful tool to predict spontaneous PTB w13, 16x. It enables
the clinician to visualize the lower uterine segment being
pulled up into the uterine corpus, the unrolling of the
endocervical os/sphincter and the excavation of the
internal endocervical canal. The short cervix has been
extensively studied and described as the anatomical
manifestation of a final common pathway in the patho-
logic syndrome of preterm parturition w18, 20x.
The two most common treatments for an ultrasound-
diagnosed short cervix in the mid-trimester are cervical
cerclage and progesterone supplementation. Cerclage
therapy continues to be utilized despite clinical trials
challenging its effectiveness w4, 21, 22x. Progesterone
supplementation has become a standard treatment to
prevent recurrent spontaneous PTB, and most recently
has been shown to reduce spontaneous PTB by 44% in
women with a short cervix w6, 14x. However, no studies
to date have compared the two treatments in a random-
ized trial.
We hypothesized that patients who received weekly
intramuscular injections of 17OHP-C will experience few-
er spontaneous PTB prior to 35 weeks’ gestation com-
pared to patients treated with cerclage. The purpose of
this study was to determine pregnancy outcomes in
patients with ultrasound-diagnosed short cervix in the
mid-trimester receiving medical therapy with 17OHP-C
compared to surgical therapy with McDonald cerclage.
Material and methods
Under an Institutional Review Board approved protocol, single-
ton pregnancies presenting to the Lehigh Valley Hospital Peri-
natal Testing Center between November 2003 and December
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Figure 1 Treatment protocol. PPROMspreterm premature rupture of membranes.
2006 with risk factors for spontaneous PTB were screened with
serial transvaginal ultrasound beginning at 16 weeks gestation.
Risk factors for PTB included history of spontaneous PTB, se-
cond-trimester pregnancy loss, previous cervical surgery (coni-
zation or loop excision), or documented uterine anomaly. Also
low-risk, asymptomatic singleton pregnancies between 16 and
24 weeks’ gestation were screened for evidence of cervical
shortening with transabdominal ultrasound as part of routine
anatomical survey. If the cervix appeared short (F25 mm) trans-
abdominally, a transvaginal ultrasound was performed. Trans-
vaginal CL measurement was obtained using the standardized
technique described by Rust et al. w21x.
Patients with ultrasonographic evidence of short cervix,
defined as a transvaginal CL F25 mm, were offered enrollment
into study. Exclusion criteria included any known fetal chromo-
somal or structural anomaly, multiple gestation, known allergy
to progesterone, ruptured membranes, vaginal bleeding, evi-
dence of an active intra-amniotic infection (diagnosed clinically
or by amniocentesis), prolapse of endocervical membranes
beyond the external cervical os, persistent uterine activity
accompanied by cervical change, or an obstetrically indicated
delivery.
Patients who met the study inclusion criteria and provided
informed written consent were enrolled in the study. Manage-
ment of the study population is detailed in Figure 1. Patients
were hospitalized for inpatient bed rest, transabdominal amnio-
centesis to exclude intra-amniotic infection, a complete blood
count, a pelvic examination, cervico-vaginal fetal fibronectin
sampling 24 h after the last pelvic exam, urogenital cultures for
Chlamydia trachomatis, Neisseria gonorrhea, Mycoplasma
hominis, Ureaplasma urealyticum, Group B streptococcus,
Gardnerella vaginalis, and a urine culture. Empiric treatment with
indomethacin (100 mg orally followed by 50 mg every 6 h) and
clindamycin (900 mg intravenous every 8 h) was initiated for
48–72 h. After this initial treatment, all patients underwent repeat
transvaginal ultrasound to exclude rapidly progressing cervical
shortening and prolapse of membranes beyond the external
cervical os.
Randomization was accomplished by computer generated
assignment to McDonald cerclage or 17OHP-C. Assignments
were concealed in sequentially numbered opaque envelopes by
a co-ordinator not involved in screening, enrollment, or random-
ization. The randomization sequence was secured by adminis-
trative staff until enrollment was terminated. Participants were
enrolled by maternal fetal medicine physicians or certified nurse
practitioners. Randomization was accomplished by handing out
the sequentially numbered opaque envelops. Due to the intrinsic
nature of the study design, there was no masking in this trial.
Patients were assigned to either McDonald cerclage (active con-
trol group) or weekly administration of 17OHP-C (intervention
group). The cerclage group received a single stitch McDonald
cerclage with 1-0 Prolene (Ethicon, Inc. Somerville, NJ) placed
by a maternal-fetal medicine physician under regional anesthe-
sia. If necessary, prolapse of endocervical membranes was
reduced by either retrograde filling the bladder with 500 cc of
sterile normal saline solution and/or transcervical placement of
a 16F Foley catheter.
The 17OHP-C group received weekly intramuscular injections
of 250 mg 17 a-hydroxyprogesterone caproate by a registered
nurse at the weekly follow-up CL measurements. Compliance
was ensured by weekly contact with the patient. Any missed
appointment was followed up with perinatal nurse contact and
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Figure 2 Distribution of study participants.
evaluation of access to care. These injections were started upon
randomization and administered weekly until 36 weeks’
gestation.
Patients were educated to promptly report signs and symp-
toms of preterm labor, advised to follow modified bed rest, and
were scheduled for weekly outpatient follow-up visits with
transvaginal ultrasound. At gestational ages prior to 24 weeks,
a rescue cerclage was allowed under this protocol if membranes
prolapsed beyond the level of the cerclage in the cerclage group
or if membranes prolapsed beyond the level of the external os
in the 17OHP-C group. Treatment was discontinued at
36 weeks’ gestation, including cerclage removal if applicable.
Cerclage was removed on an emergent basis for the following
clinical scenarios: rupture of membranes, preterm labor placing
tension of the cerclage and refractory to tocolytic therapy, pre-
term labor with contraindications to tocolytic therapy, clinical
diagnosis of chorioamnionitis or abruptio placentae. Antepar-
tum, intrapartum, and postpartum care were by standard obstet-
rical practice. No ultrasound-indicated cerclages were placed
outside the study protocol.
The primary outcome was spontaneous PTB prior to
35 weeks’ gestation. Secondary outcomes included obstetrical
complications and neonatal morbidity and mortality. Obstetric
complications included chorioamnionitis, abruptio placentae,
preterm premature rupture of membranes (PPROM), need for a
rescue procedure, days from study enrollment to delivery, and
gestational age at delivery. Neonatal morbidity was stratified as
follows: no morbidity was defined as no neonatal intensive care
admission and routine newborn care; mild morbidity was defined
as neonatal intensive care admission without severe morbidity;
severe morbidity was defined as life threatening morbidity
including respiratory distress syndrome requiring mechanical
ventilation )24 h, intraventricular hemorrhage, neonatal sepsis,
or necrotizing enterocolitis. Perinatal death included any stillbirth
or neonatal death during the study period. Study group com-
parisons included maternal age, race, parity, insurance type, and
gestational age at study entry. Risk factors for spontaneous PTB
analyzed included prior second trimester loss between 16 and
23 weeks’ gestation, prior spontaneous PTB between 24 and
36 weeks’ gestation, earliest PTB, prior cervical surgery, fetal
fibronectin status, positive urogenital culture, mu¨llerian anomaly,
digital cervical exam, width and depth of prolapse of fetal mem-
branes into the endocervical canal, distal CL and post-cerclage
CL. A post hoc subgroup analysis comparing the effect of cer-
clage to 17OHP-C on gestational age at delivery in patients with
a CLF15 mm and a previous PTB was performed.
In a previous study, the incidence of PTB in a similar cohort
of patients (asymptomatic, short cervix) who received cerclage
was ;45% w4x. We calculated to have 80% power to detect a
50% reduction in spontaneous PTB prior to 35 weeks’ gestation,
77 patients were required for each study arm with a two-tailed
a-0.05. An interim analysis was planned and completed when
half the study participants were enrolled and delivered.
Tests of association between the cerclage and 17OHP-C
groups were performed using Pearson’s x2, Fisher’s exact, and
Student’s t-test (or non-parametric equivalents) where appropri-
ate. The relative risks of developing specific complications in the
cerclage group as compared to the 17OHP-C group were cal-
culated. Cox proportional hazards models was constructed to
evaluate for differences between the two treatment groups for
delivery prior to 35 weeks. Kaplan-Meier curves were generated
to compare gestational age at birth by treatment group. All sta-
tistical analysis was performed on an intention-to-treat basis
using STATA 9.2 (StataCorp LP, College Station, TX) and used a
two-tailed a of 0.05.
Results
Of the 91 consecutive patients who met study inclusion
criteria and were offered enrollment into the study pro-
tocol, eight declined randomization, two experienced
PPROM prior to randomization, and two had evidence of
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Table 2 Risk factors for spontaneous preterm birth.
Variable Cerclage (ns42) 17OHP-C (ns37) P-value
Prior 2nd trimester loss 16–23 weeks 9 (21.4) 6 (16.2) 0.58
Prior preterm birth 24–36 weeks 16 (16) 11 (29.7) 0.48
Earliest preterm birth (week) 25.3"5.9 25.7"5.4 0.83
Distal cervical length (mm) 14.5"6.6 16.8"5.1 0.11
Width of funnel (mm) 13.4"4.9 14.3"7.7 0.56
Depth of funnel (mm) 20.1"11.2 14.2"7.4 0.02
Digital examination
Dilatation (cm) -1 cm -1 cm 0.84
Effacement 25% 37% 0.08
Station –3 –3 0.48
Prior cervical surgery 12 (28.6) 5 (13.9) 0.17
Mu¨llerian anomaly 0 (0.0) 0 (0.0) 0.99
Bacterial vaginosis 2 (4.8) 8 (21.6) 0.04
U. urealyticum* 23 (54.8) 21 (60.0) 0.64
M. hominis 8 (19.1) 9 (25.7) 0.58
Group B streptococcus** 9 (22.0) 4 (11.8) 0.25
C. trachomatis 0 (0.0) 0 (0.0) 0.99
N. gonorrhea 1 (2.4) 0 (0.0) 0.35
q Fetal fibronectin*** 11 (29.7) 8 (25.0) 0.66
Data are n (%) or mean"standard deviation. *Data available on 77 out of 79 patients. **Data available on 75 out of 79 patients.
***Data available on 69 out of 79 patients.
Table 1 Demographic characteristics.
Characteristic Cerclage 17OHP-C
(ns42) (ns37)
Age (years) 29.6"7.15 27.6"6.58
Race
Caucasian 18 (42.9) 16 (43.2)
Hispanic 16 (38.1) 11 (29.7)
African American 7 (16.7) 9 (24.3)
Other 1 (2.4) 1 (2.7)
Private insurance 16 (38.1) 15 (40.5)
Multiparity 29 (69.0) 22 (59.5)
Gestational age at entry (week) 20.0"6.41 20.9"5.89
Data are n (%) or mean"standard deviation.
intra-amniotic infection diagnosed by amniocentesis
(positive amniotic fluid culture and intra-amniotic glucose
-10 mg/dL). Seventy-nine patients remained: 42 ran-
domized to the cerclage group and 37 randomized to the
17OHP-C group (Figure 2). There were no patients who
were lost to follow-up or non-compliant with 17OHP-C
therapy. There were no indicated PTB in either study
group. There were no complications from amniocentesis
or any adverse clinical outcomes to indomethacin or anti-
biotic therapy. None of the patients in either study group
demonstrated rapidly progressing cervical shortening or
prolapse of endocervical membranes beyond the exter-
nal os on repeat transvaginal ultrasound after the initial
48–72 h treatment period.
There were no differences in demographic character-
istics of patients in each study group (Table 1). There
were no statistically significant differences between the
two treatment groups with regard to history of a previous
second trimester loss, previous PTB, earliest gestational
age of previous PTB, prior cervical surgery (Table 2). Dig-
ital pelvic examinations and transvaginal CL measure-
ments at study enrollment were similar between both
groups. There was no difference in distal CL or width of
endocervical funnel between groups. However, patients
in the cerclage group had a more pronounced prolapse
of chorio-amniotic membranes (Ps0.02); while patients
in the 17OHP-C group were more likely to have bacterial
vaginosis (Ps0.04). The mean post-cerclage CL was
35 mm, compared to a 14.5 mm mean pre-cerclage CL.
There was no difference in genital culture results between
the two study groups.
Analysis of obstetric and neonatal outcome demon-
strated no difference between the cerclage group and the
17OHP-C group with respect to chorioamnionitis, abrup-
tio placentae, PPROM, need for rescue procedure, or
neonatal morbidity (Table 3). The primary outcome of
spontaneous PTB prior to 35 weeks’ gestation occurred
equally in both study groups (38.1% vs. 43.2%; relative
risk, 1.14; 95% CI, 0.67, 1.93). Mean gestational age at
delivery was similar in both study groups with the cer-
clage group and 17OHP-C group delivering at 32.9"
6.4 weeks and 33.0"5.9 weeks, respectively (Ps0.96).
Cox regression analysis adjusting for gestational age
at trial enrollment demonstrated no significant difference
in delivery prior to 35 weeks’ gestation (Ps0.75). Kaplan-
Meier curve is shown in Figure 3. There was no statistical
difference in women with CL F25 mm delivering pre-
maturely at gestational ages prior to 24, 28, 32, 35, or
37 weeks, respectively. However, there did appear to be
a benefit to cerclage when evaluating those patients with
a CL F15 mm (ns37; 22 cerclage and 15 17OHP-C).
The cerclage group experienced a significant reduction
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Table 3 Primary and secondary outcomes.
Outcome Cerclage (ns42) 17OHP-C (ns37) RR (95% CI) P-value
Gestational age at delivery (weeks) 32.9"6.4 33.0"5.9 0.96
Days from enrollment to birth 92.2"40.9 84.8"38.6 0.41
Chorioamnionitis 12 (28.6) 8 (21.6) 0.76 (0.35, 1.65)
Abruptio placentae 3 (7.5) 6 (17.1) 2.27 (0.61, 8.44)
PPROM 13 (32.5) 13 (37.1) 1.14 (0.61, 2.12)
Rescue procedure 4 (9.5) 5 (13.5) 1.42 (0.41, 4.89)
Preterm birth CL F25 mm
-37 weeks gestation 22 (52.4) 22 (59.4) 1.14 (0.77, 1.68)
-35 weeks gestation 16 (38.1) 16 (43.2) 1.14 (0.67, 1.93)
-32 weeks gestation 15 (35.7) 13 (35.1) 0.98 (0.54, 1.79)
-28 weeks gestation 10 (23.8) 7 (18.9) 0.79 (0.34, 1.88)
-24 weeks gestation 5 (11.9) 3 (8.1) 0.68 (0.17, 2.66)
Preterm birth CL F15 mm*
-37 weeks gestation 10 (45.5) 13 (86.7) 0.52 (0.32, 0.86)
-35 weeks gestation 7 (31.8) 10 (66.7) 0.48 (0.24, 0.97)
-32 weeks gestation 7 (31.8) 8 (53.3) 0.60 (0.27, 1.29)
-28 weeks gestation 5 (22.7) 5 (33.3) 0.68 (0.24, 1.95)
-24 weeks gestation 3 (13.6) 3 (20.0) 0.68 (0.17, 2.75)
Neonatal morbidity (%) 0.34
None 28 (66.7) 21 (56.8)
Mild 1 (2.3) 5 (13.5)
Severe 9 (21.4) 7 (18.9)
Death 5 (11.9) 4 (10.8)
Data are n (%) or mean"standard deviation. PPROMspreterm premature rupture of membranes, CLscervical length, RRsrelative
risk, CIs95% confidence interval. *Cerclage (ns22); 17OHP-C (ns15).
Figure 3 Kaplan-Meier survival curve analysis with respect
to gestational age at delivery. Blue line, cerclage; Red line,
17OHP-C.
in spontaneous PTB -35 weeks (31.8%) compared to
the 17OHP-C group (66.7%) (Table 3).
Perinatal outcome for the eight patients who declined
study enrollment and treated with expectant manage-
ment with serial transvaginal surveillance were similar to
the 17OHP-C and cerclage groups. The four patients
receiving a cerclage revision delivered at 21, 24, 24,
31 weeks, respectively. The five patients initially assigned
to 17OHP-C who received a rescue cerclage delivered at
28, 35, 37, 38, 39 weeks, respectively. An analysis of the
42 patients with a previous spontaneous PTB showed
no difference in primary and secondary pregnancy out-
comes between treatment groups.
Discussion
The diagnosis of midtrimester cervical shortening is a
puzzle for practicing clinicians. Numerous studies have
demonstrated the reliability and reproducibility of CL
measurements in providing a risk assessment of spon-
taneous PTB w2, 11–13, 16x. However, despite its use-
fulness in identifying those at highest risk of premature
birth, the American College of Obstetricians and Gyne-
cologists has cautioned against the routine use of trans-
vaginal ultrasound due to the lack of effective treatment
options w1x.
However, new data have been published in an attempt
to validate progesterone supplementation as an effective
treatment for cervical shortening. Fonseca et al. w6x dem-
onstrated a 44% reduction in spontaneous PTB prior to
34 weeks in patients with a CL F15 mm using 200 mg
intravaginal progesterone daily between 24 and
34 weeks’ gestation. Another randomized controlled trial
utilized 100 mg of daily intravaginal progesterone sup-
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plementation in high-risk singleton pregnancies with a
previous PTB, cervical insufficiency or a Mu¨llerian anom-
aly, showing a 49% reduction of spontaneous PTB in the
progesterone group w7x.
Our goal was to determine pregnancy outcome in
asymptomatic women with short cervix in the mid-tri-
mester who were randomly assigned to treatment with
McDonald cerclage compared to weekly intramuscular
injections of 17OHP-C. This study did not demonstrate
a significant improvement in reducing spontaneous PTB
prior to 35 weeks’ gestation among participants with a
CL F25 mm who received 17OHP-C as compared to
McDonald cerclage. We found no difference in obstetric
or neonatal outcomes, including our primary outcome of
spontaneous PTB prior to 35 weeks’ gestation in our
patient population.
There are several possible explanations for our results
and analysis of these data should be interpreted with
caution. First, we recognize that we are underpowered to
detect a 50% reduction in spontaneous PTB between
study groups. We anticipated randomizing 160 patients
to allow for attrition during the study. However, the trial
was stopped early by the authors because after 3 years
of recruitment, an interim analysis showed no difference
in outcome between treatment groups. With new data
being presented regarding the benefits of progesterone
supplementation, we felt it was impractical, unethical,
and unreasonable to withhold progesterone from one
study group to achieve our enrollment goal. Thus, we
may be unable to identify a benefit of 17OHP-C com-
pared to cerclage due to type II error. We felt that by
publishing these data, it would allow for inclusion in a
meta-analysis with other similarly designed clinical trials.
Alternatively, weekly supplementation with 250 mg of
17OHP-C may be as effective as cerclage therapy in pre-
venting spontaneous PTB in patients with CL F25 mm.
There are discrepancies in the literature regarding the
optimal dose and formulation of progesterone supple-
mentation in reducing spontaneous PTB. Patient hetero-
geneity, use of different progestational agents, and route
of delivery may account for the diversity in outcomes. We
chose the synthetic caproate esther formulation of pro-
gesterone (17OHP-C) because it has been shown to
reduce spontaneous PTB in high-risk patients with a pre-
vious PTB. 17OHP-C differs from natural progesterone in
composition and route of administration. Since 17OHP-
C is a long acting progestogen that is only structurally
related to natural progesterone, it may not convey iden-
tical clinical response as natural progesterone. Also, local
vaginal absorption of natural progesterone may quell site
specific inflammation in the cervico-vaginal microenvi-
ronment. A different dose, formulation or route of delivery
may have a more beneficial effect on reducing sponta-
neous PTB.
Although, progesterone has anti-inflammatory effects
and plays a key role in uterine quiescence, the precise
mechanism of how 17OHP-C prevents premature par-
turition is poorly understood. Investigators have identified
anti-inflammatory properties, prevention of prostaglandin
production, altered gene expression, inhibition of oxyto-
cin binding and gap junction formation, as progester-
one’s contribution of pregnancy maintenance w3, 8, 9,
15x. Progesterone may also contribute to the cervix’s
ability to act as a guard against the upward passage of
potentially harmful agents and to maintain the compe-
tence of the lower uterine segment and endocervical
sphincter. However, if a subacute upper genital tract
infection is present once the cervix is short and funneled,
as in our study, 17OHP-C may not be effective in reduc-
ing the rate of spontaneous PTB in these patients.
The strength of this study is that it is a randomized trial
comparing two treatments for ultrasound-diagnosed
short cervix. We compared intervention with 17OHP-C
to McDonald cerclage. The Kaplan-Meier survival curve
demonstrates no apparent difference in gestational age
at delivery or spontaneous PTB prior to 35 weeks’ ges-
tation, corresponding well with the perinatal outcomes
data between study groups. 17OHP-C appears to be at
least as effective as cerclage in treating patients with
CL F25 mm. However, cerclage may be superior to
17OHP-C in reducing premature birth in patients with
shorter CL (F15 mm) due to initiation of uterine myo-
metrial contractions w19x.
We caution interpretation of these data as conclusive
until a large, adequately powered multi-center trial can be
performed to address this clinical question. Although the
benefit of cerclage in women with a CL F15 mm is in
agreement with recently published data, our study was
conservatively underpowered to show if weekly 17OHP-
C was superior to cerclage in reducing spontaneous PTB
w17x. Weekly injections of 17OHP-C may be insufficient
to extend pregnancy in women with shortened CL in the
midtrimester, but daily vaginal progesterone therapy may
be a better consideration. These data, coupled with
recently published data on this subject w5–7, 17x, will
hopefully encourage more investigation comparing med-
ical and surgical treatments for short cervix.
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